AJJ Medtech Secures S\$3 Million Multi-Year Institutional Contract for Biodegradable Medical Consumables

Key Highlights

• AJJ Medtech Holdings Limited, via its wholly owned subsidiary AJJ Healthcare Management Pte. Ltd., has secured a four-year supply contract valued at approximately S\$3 million with a network of Singapore healthcare institutions.
• The contract begins 1 June 2026, with an initial tenure of two years and an option to extend for an additional two years, providing recurring revenue visibility over the four-year period.
• This latest win further strengthens AJJ Medtech’s base of institutional healthcare customers and aligns with the company’s long-term sustainability and Environmental, Social and Governance (ESG) strategy.
• Including this agreement, the Group’s cumulative institutional orderbook now exceeds S\$8 million, with revenue recognition scheduled over the next three to five years.
• The new contract focuses on the supply of biodegradable medical consumables, directly supporting Singapore healthcare institutions’ shift towards environmentally responsible procurement practices.

Details and Strategic Significance

AJJ Medtech Holdings Limited (“AJJ Medtech”), listed on the Singapore Exchange (SGX: 584), announced a significant milestone with the securing of a S\$3 million institutional contract for the supply of biodegradable medical consumables to a network of Singapore healthcare institutions.

The contract, which commences on 1 June 2026, is for an initial period of two years, with an optional extension for another two years. This adds substantial recurring revenue visibility for the Group, a key indicator of future financial stability and ongoing demand for AJJ’s product offerings.

This new contract adds to a series of institutional tenders recently won by AJJ Healthcare, further validating the company’s competitive execution capabilities in the healthcare supply space. With this and other recent multi-year agreements to supply both medical and laboratory consumables, AJJ Medtech’s institutional revenue pipeline now exceeds S\$8 million, with contracts spanning three to five years. This provides a strong foundation of secured, recurring revenue and reinforces the Group’s position as a reliable supply partner to Singapore’s healthcare sector.

Impact on Shareholders and Potential Price Sensitivity

• Strengthened Recurring Revenue Base: The addition of this multi-year contract enhances AJJ’s revenue visibility and stability, which is a positive signal for investors seeking long-term growth and reduced earnings volatility.
• Strategic Positioning for Sustainability: The contract focuses on biodegradable medical consumables, supporting both the Group’s and its institutional partners’ ESG commitments. This sector is gaining increasing attention from investors and regulators, especially as Singapore’s healthcare sector is responsible for around 7% of national carbon emissions.
• ESG-Led Growth: Management highlighted that this contract marks tangible progress in the company’s ESG-led growth strategy, helping healthcare institutions switch from traditional plastics to biodegradable options—a move that directly aligns with Singapore’s climate objectives.
• Expansion into Higher-Value Solutions: Beyond consumables, AJJ Medtech continues to develop higher-value technologies such as multifunctional humanoid eldercare robots and intelligent healthcare applications. This signals a transformation from a consumables supplier to a comprehensive healthcare technology platform provider.
• Financial Impact: While the contract is not expected to have a material impact on Net Tangible Assets or Earnings Per Share for the current financial year, it is expected to contribute positively to the Group’s financial performance throughout the four-year tenure. Investors should consider the long-term nature of the revenue recognition.

Management Commentary

Mr. William Ong, CEO of AJJ Healthcare:

“With the healthcare sector contributing around 7% of Singapore’s carbon emissions, as highlighted in a recent National University of Singapore – Ministry of Health report, this partnership marks tangible progress in our ESG-led growth. By enabling our healthcare partners to switch from conventional plastics to biodegradable alternatives, we deliver a clear, measurable environmental benefit that directly supports Singapore’s climate objectives.”

Miss Alice Zhao, CEO of AJJ Medtech:

“Securing this long-term institutional contract reflects our continued execution in competitive healthcare tenders and strengthens the foundation of secured, recurring revenue for the Group. At the same time, we are progressively broadening our portfolio—from environmentally responsible medical consumables to higher-technology healthcare solutions such as robotics and intelligent applications. Our focus remains on disciplined execution, building long-term institutional partnerships, and developing a sustainable healthcare platform that creates enduring value over time.”

About AJJ Medtech Holdings Limited

AJJ Medtech Holdings Limited is a leader in healthcare technology, providing integrated medtech solutions across Singapore and Southeast Asia. The company has evolved from a supplier of basic consumables into a provider of comprehensive turnkey solutions, including supply chain management, digital healthcare platforms, artificial intelligence, and robotics. This transformation underscores the company’s ambition to become a full-spectrum healthcare technology platform.

Investor Takeaway

This contract win is significant for investors as it builds AJJ Medtech’s base of secured, recurring revenue and advances its sustainability initiatives, both of which are increasingly important factors in institutional investment and share price performance. The Group’s growing portfolio of long-term institutional contracts not only strengthens its competitive position but also lays the groundwork for further expansion into higher-value, technology-driven healthcare solutions.

The announcement is price-sensitive as it increases the company’s orderbook, enhances revenue visibility, and signals strategic execution in both market positioning and sustainability. Investors may respond positively to the strengthened outlook for stable revenue, ongoing ESG progress, and the move into advanced healthcare technology applications.

Disclaimer: The information provided in this article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors are advised to conduct their own research or consult with a qualified financial advisor before making any investment decisions. While efforts have been made to ensure accuracy, no guarantees are made regarding the completeness or reliability of the information presented.

View AJJ Medtech Historical chart here